Skip to content
DataLookout
Menu

NCT04093466

A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors

StatusUnknown
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Primary completion date: Nov 2022 to Oct 2025
    • Study completion date: Nov 2022 to Dec 2025
    v6
  3. Notable Primary completion date: Nov 2021 to Nov 2022v5
  4. Notable Eligibility criteria shortened, about 38 wordsv4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2020 to Apr 27, 2020
    • Site details revised
    v3
  6. Notable Start date: Nov 2019 to May 2020v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of dose-limiting toxicities (DLTs) by NCI CTCAE 5.0: Dose Escalation Stage
Timeframe: First 5 weeks after initial administration of CX1003
Maximum tolerated dose (MTD): Dose Escalation Stage
Timeframe: First 5 weeks after initial administration of CX1003

Secondary (11)

Pharmacokinetics (PK) profile: Cmax
Pharmacokinetics (PK) profile: Tmax
Pharmacokinetics (PK) profile: T1/2
Pharmacokinetics (PK) profile: AUC
Pharmacokinetics (PK) profile: CL/F
Show 6 moreShow less
Pharmacokinetics (PK) profile: Vz/F
Objective Response Rate (ORR)
Progression-free survival (PFS)
Disease Control Rate (DCR)
Duration of Response (DOR)
Safety profile as assessed by the incidence, duration, and severity of adverse events

Arms and interventions

Treatment (CX1003)Experimental

Treatment will comprise 2 periods: a 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond).

Drugs: CX1003

Sites

1 site in 1 country

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, Beijing Municipality, China